BCMA CAR-T for CNS Myeloma: Is It Safe and Effective for Brain or Spinal Fluid Disease? | IMS 2026

Sven Neubert of University Hospital Würzburg discusses BCMA CAR-T outcomes in myeloma involving the brain or spinal fluid (CNS myeloma) at IMS 2026 in Glasgow. These patients face the hardest outlook and are usually left out of CAR-T trials. A study from 11 centers in Germany and Switzerland found commercial BCMA CAR-T was safe and active, with no extra safety concerns, though outcomes still trail non-CNS disease. Learn why bridging therapy is challenging and why these patients should not be excluded from CAR-T.

Timestamps:

0:00 Introduction

0:15 What is CNS myeloma?

1:26 The study: 11 centers in Germany and Switzerland

1:46 Safety results

2:24 Response and remission rates

3:00 What predicted better outcomes

3:42 The message: help patients get CAR-T

3:57 Why bridging therapy is difficult

4:45 Did patients reach remission before CAR-T?

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.